The permanent injunction highlights the successful defense of Insulet’s intellectual property. Subsequently, the damages award was reduced from $452 million to $60 million at Insulet’s election. The company wanted the permanent injunction instead of the higher damages account.

Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point going to be acquired by Medtronic for $738 million. However, Medtronic called the deal off in December 2023, citing “multiple breaches” to their acquisition agreement.

Late last year, Insulet announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. A jury found that EOFlow and several other defendants misappropriated Insulet’s trade secrets. Insulet was awarded $170 million in compensatory damages from EOFlow. The Acton, Massachusetts-based company also received an additional $282 million in exemplary damages from EOFlow. Those damages, covering “willful and malicious misappropriation,” brought the total award to $452 million. Insulet said at the time that it had no certainty over EOFlow’s ability to satisfy the damages.